In vitro adenosine triphosphate based chemotherapy response assay in gastric cancer

Seulkee Park, Yanghee Woo, Hogeun Kim, Yong Chan Lee, Sungho Choi, Woo Jin Hyung, Sung Hoon Noh

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Purpose: The purpose of this study was to investigate the reliability and the clinical applicability of the adenosine-triphosphate-based chemotherapy response assay (ATP-CRA) as a method of determining in vitro chemosensitivity in patients with gastric cancer. Materials and Methods: A total of 243 gastric cancer tissue samples were obtained from gastrectomies performed between February 2007 and January 2010. We evaluated the effectiveness of the ATP-CRA assay in determining the chemosensitivity of gastric cancer specimens using eleven chemotherapeutic agents - etoposide, doxorubicin, epirubicin, mytomicin, 5-fluorouracil, oxaliplatin, irinotecan, docetaxel, paclitaxel, methotraxate, and cisplatin - for chemosensitivity studies using ATP-CRA. We assessed the failure rate, the cell death rate, and the chemosensitivity index. Results: The failure rate of ATP-CRA was 1.6% (4/243). The mean coefficient of variation for triplicate ATP measurements was 6.5%. Etoposide showed the highest cell death rate (35.9%) while methotrexate showed the lowest (16.6%). The most active chemotherapeutic agent was etoposide, which most frequently ranked highest in the chemosensitivity test: 31.9% (51/160). Oxaliplatin was more active against early gastric cancers than advanced gastric cancers, whereas docetaxel was more active against advanced cancers. The lymph node negative group showed a significantly higher cell death rate than the lymph node positive group when treated with doxorubicin, epirubicin, and mitomycin. Conclusions: ATP-CRA is a stable and clinically applicable in vitro chemosensitivity test with a low failure rate. The clinical usefulness of ATP-CRA should be evaluated by prospective studies comparing the regimen guided by ATP-CRA with an empirical regimen.

Original languageEnglish
Pages (from-to)155-161
Number of pages7
JournalJournal of Gastric Cancer
Volume10
Issue number4
DOIs
Publication statusPublished - 2010 Dec 1

Fingerprint

Stomach Neoplasms
Adenosine Triphosphate
Drug Therapy
oxaliplatin
docetaxel
Etoposide
Epirubicin
irinotecan
Cell Death
Doxorubicin
Mortality
Lymph Nodes
In Vitro Techniques
Mitomycin
Gastrectomy
Methotrexate
Fluorouracil
Prospective Studies
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Gastroenterology
  • Cancer Research

Cite this

Park, Seulkee ; Woo, Yanghee ; Kim, Hogeun ; Lee, Yong Chan ; Choi, Sungho ; Hyung, Woo Jin ; Noh, Sung Hoon. / In vitro adenosine triphosphate based chemotherapy response assay in gastric cancer. In: Journal of Gastric Cancer. 2010 ; Vol. 10, No. 4. pp. 155-161.
@article{85b0da72609d440f808b984a2c7d0608,
title = "In vitro adenosine triphosphate based chemotherapy response assay in gastric cancer",
abstract = "Purpose: The purpose of this study was to investigate the reliability and the clinical applicability of the adenosine-triphosphate-based chemotherapy response assay (ATP-CRA) as a method of determining in vitro chemosensitivity in patients with gastric cancer. Materials and Methods: A total of 243 gastric cancer tissue samples were obtained from gastrectomies performed between February 2007 and January 2010. We evaluated the effectiveness of the ATP-CRA assay in determining the chemosensitivity of gastric cancer specimens using eleven chemotherapeutic agents - etoposide, doxorubicin, epirubicin, mytomicin, 5-fluorouracil, oxaliplatin, irinotecan, docetaxel, paclitaxel, methotraxate, and cisplatin - for chemosensitivity studies using ATP-CRA. We assessed the failure rate, the cell death rate, and the chemosensitivity index. Results: The failure rate of ATP-CRA was 1.6{\%} (4/243). The mean coefficient of variation for triplicate ATP measurements was 6.5{\%}. Etoposide showed the highest cell death rate (35.9{\%}) while methotrexate showed the lowest (16.6{\%}). The most active chemotherapeutic agent was etoposide, which most frequently ranked highest in the chemosensitivity test: 31.9{\%} (51/160). Oxaliplatin was more active against early gastric cancers than advanced gastric cancers, whereas docetaxel was more active against advanced cancers. The lymph node negative group showed a significantly higher cell death rate than the lymph node positive group when treated with doxorubicin, epirubicin, and mitomycin. Conclusions: ATP-CRA is a stable and clinically applicable in vitro chemosensitivity test with a low failure rate. The clinical usefulness of ATP-CRA should be evaluated by prospective studies comparing the regimen guided by ATP-CRA with an empirical regimen.",
author = "Seulkee Park and Yanghee Woo and Hogeun Kim and Lee, {Yong Chan} and Sungho Choi and Hyung, {Woo Jin} and Noh, {Sung Hoon}",
year = "2010",
month = "12",
day = "1",
doi = "10.5230/jgc.2010.10.4.155",
language = "English",
volume = "10",
pages = "155--161",
journal = "Journal of Gastric Cancer",
issn = "2093-582X",
publisher = "Korean Gastric Cancer Association",
number = "4",

}

In vitro adenosine triphosphate based chemotherapy response assay in gastric cancer. / Park, Seulkee; Woo, Yanghee; Kim, Hogeun; Lee, Yong Chan; Choi, Sungho; Hyung, Woo Jin; Noh, Sung Hoon.

In: Journal of Gastric Cancer, Vol. 10, No. 4, 01.12.2010, p. 155-161.

Research output: Contribution to journalArticle

TY - JOUR

T1 - In vitro adenosine triphosphate based chemotherapy response assay in gastric cancer

AU - Park, Seulkee

AU - Woo, Yanghee

AU - Kim, Hogeun

AU - Lee, Yong Chan

AU - Choi, Sungho

AU - Hyung, Woo Jin

AU - Noh, Sung Hoon

PY - 2010/12/1

Y1 - 2010/12/1

N2 - Purpose: The purpose of this study was to investigate the reliability and the clinical applicability of the adenosine-triphosphate-based chemotherapy response assay (ATP-CRA) as a method of determining in vitro chemosensitivity in patients with gastric cancer. Materials and Methods: A total of 243 gastric cancer tissue samples were obtained from gastrectomies performed between February 2007 and January 2010. We evaluated the effectiveness of the ATP-CRA assay in determining the chemosensitivity of gastric cancer specimens using eleven chemotherapeutic agents - etoposide, doxorubicin, epirubicin, mytomicin, 5-fluorouracil, oxaliplatin, irinotecan, docetaxel, paclitaxel, methotraxate, and cisplatin - for chemosensitivity studies using ATP-CRA. We assessed the failure rate, the cell death rate, and the chemosensitivity index. Results: The failure rate of ATP-CRA was 1.6% (4/243). The mean coefficient of variation for triplicate ATP measurements was 6.5%. Etoposide showed the highest cell death rate (35.9%) while methotrexate showed the lowest (16.6%). The most active chemotherapeutic agent was etoposide, which most frequently ranked highest in the chemosensitivity test: 31.9% (51/160). Oxaliplatin was more active against early gastric cancers than advanced gastric cancers, whereas docetaxel was more active against advanced cancers. The lymph node negative group showed a significantly higher cell death rate than the lymph node positive group when treated with doxorubicin, epirubicin, and mitomycin. Conclusions: ATP-CRA is a stable and clinically applicable in vitro chemosensitivity test with a low failure rate. The clinical usefulness of ATP-CRA should be evaluated by prospective studies comparing the regimen guided by ATP-CRA with an empirical regimen.

AB - Purpose: The purpose of this study was to investigate the reliability and the clinical applicability of the adenosine-triphosphate-based chemotherapy response assay (ATP-CRA) as a method of determining in vitro chemosensitivity in patients with gastric cancer. Materials and Methods: A total of 243 gastric cancer tissue samples were obtained from gastrectomies performed between February 2007 and January 2010. We evaluated the effectiveness of the ATP-CRA assay in determining the chemosensitivity of gastric cancer specimens using eleven chemotherapeutic agents - etoposide, doxorubicin, epirubicin, mytomicin, 5-fluorouracil, oxaliplatin, irinotecan, docetaxel, paclitaxel, methotraxate, and cisplatin - for chemosensitivity studies using ATP-CRA. We assessed the failure rate, the cell death rate, and the chemosensitivity index. Results: The failure rate of ATP-CRA was 1.6% (4/243). The mean coefficient of variation for triplicate ATP measurements was 6.5%. Etoposide showed the highest cell death rate (35.9%) while methotrexate showed the lowest (16.6%). The most active chemotherapeutic agent was etoposide, which most frequently ranked highest in the chemosensitivity test: 31.9% (51/160). Oxaliplatin was more active against early gastric cancers than advanced gastric cancers, whereas docetaxel was more active against advanced cancers. The lymph node negative group showed a significantly higher cell death rate than the lymph node positive group when treated with doxorubicin, epirubicin, and mitomycin. Conclusions: ATP-CRA is a stable and clinically applicable in vitro chemosensitivity test with a low failure rate. The clinical usefulness of ATP-CRA should be evaluated by prospective studies comparing the regimen guided by ATP-CRA with an empirical regimen.

UR - http://www.scopus.com/inward/record.url?scp=84867498838&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867498838&partnerID=8YFLogxK

U2 - 10.5230/jgc.2010.10.4.155

DO - 10.5230/jgc.2010.10.4.155

M3 - Article

C2 - 22076180

AN - SCOPUS:84867498838

VL - 10

SP - 155

EP - 161

JO - Journal of Gastric Cancer

JF - Journal of Gastric Cancer

SN - 2093-582X

IS - 4

ER -